DurgicalDurgical
EN
Open the app

Tumour markers: serum and tissue, and what each one is for !

  • Topic

Markers are molecules that point to a cancer: some are measured in blood to follow treatment, others are stained in the biopsy to name the tumour.

Updated 2026-11-01

What it is

Tumour markers come in two families. Tissue markers are detected in the biopsy, mostly by immunohistochemistry, and tell the pathologist what the tumour is, where it came from and which targeted treatment may work. Serum markers are measured in blood and are used mainly to support a diagnosis, estimate prognosis and follow response and relapse; almost none is good enough to diagnose or screen on its own. The biochemistry of serum markers is covered in Biochemistry; this page links each marker to its tumour and its use.

Key facts

  • Immunohistochemistry is decisive for undifferentiated tumours and for carcinoma of unknown primary.
  • Intermediate filaments point to the cell family: cytokeratin epithelial, vimentin mesenchymal, desmin muscle, GFAP glial.
  • Predictive markers (ER, HER2, PD-L1, KIT) choose treatments; prognostic markers (Ki-67) estimate behaviour.
  • Serum markers also rise in benign conditions: CEA in smokers and inflammation, CA-125 in endometriosis and pregnancy, AFP in hepatitis, PSA in prostatitis and benign hyperplasia.

Markers to know: where they are measured and what they are for

MarkerWhereTumourMain use
CytokeratinsTissueCarcinomas (epithelial)Shows the tumour is epithelial
CD45 (leukocyte common antigen), CD20, CD3TissueLymphomas (B or T)Identifies a lymphoid tumour and its lineage
S-100, SOX10, HMB-45, Melan-ATissueMelanomaConfirms melanocytic origin
Chromogranin, synaptophysinTissueNeuroendocrine tumours (carcinoid, small cell)Confirms neuroendocrine differentiation
TTF-1; CDX2TissueLung adenocarcinoma and thyroid; intestinal adenocarcinomaPoints to the primary site in a metastasis
CD117 (KIT), DOG1TissueGastrointestinal stromal tumourDiagnosis and choice of KIT inhibitor
ER, PR, HER2TissueBreast carcinomaPredict response to hormone or anti-HER2 therapy
AFPSerumHepatocellular carcinoma, yolk sac tumourDiagnosis support and follow-up; excludes pure seminoma when raised
β-hCGSerumChoriocarcinoma, molar pregnancy, testicular germ cell tumoursDiagnosis and follow-up
PSASerumProstate carcinomaFollow-up after treatment; screening only after shared decision
CEASerumColorectal and other adenocarcinomasFollow-up for recurrence; not for diagnosis
CA-125; CA 19-9SerumEpithelial ovarian carcinoma; pancreatic and biliary carcinomaFollow-up of response and relapse
CalcitoninSerumMedullary thyroid carcinomaDiagnosis support and follow-up, including MEN 2 families
Monoclonal protein (M protein), free light chainsSerum and urineMultiple myelomaDiagnosis and follow-up

Markers

  • Cytokeratin
  • Vimentin
  • Desmin
  • CD45
  • S-100
  • Chromogranin
  • TTF-1
  • CD117
  • ER/PR/HER2
  • Ki-67
  • AFP
  • β-hCG
  • PSA
  • CEA
  • CA-125
  • CA 19-9
  • Calcitonin

Clinical notes

  • Testicular tumours: AFP, β-hCG and LDH are measured before orchiectomy; a raised AFP rules out a pure seminoma.
  • A serum marker is most useful when compared with the same patient's previous value, in the same laboratory.
  • A normal marker does not exclude cancer and a raised one does not prove it; the diagnosis rests on the biopsy.
  • A metastasis of unknown origin is studied with a panel of tissue markers to find the primary site.

Test yourself

Think of the answer, then tap the question to see it.

What is the main clinical use of most serum tumour markers?

Following response to treatment and detecting relapse, by comparing values over time; they are not reliable for screening or diagnosis on their own.

A testicular tumour with a raised AFP cannot be which type?

A pure seminoma; a raised AFP points to a non-seminomatous component such as yolk sac tumour.

Which tissue marker shows that an undifferentiated tumour is a carcinoma?

Cytokeratin, an intermediate filament of epithelial cells.

Which serum marker is used in the follow-up of medullary thyroid carcinoma?

Calcitonin (often together with CEA).

Why are ER, PR and HER2 tested in every breast carcinoma?

They are predictive markers: they show whether hormone therapy or anti-HER2 therapy is likely to work.

Add to my cards (5)

Elsewhere in DurgiPedia

← All of general pathology

Educational content on the mechanisms of disease; not a diagnostic or treatment guide and no substitute for a health professional's advice. No doses are given.

Sources: Tumor Markers (National Cancer Institute (NCI), 2026); Tumor Marker Tests: MedlinePlus Medical Test (MedlinePlus, US National Library of Medicine, 2026); Testicular Cancer (StatPearls (NCBI Bookshelf), 2024).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.